Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Daniel A. Pollyea, Martin S. Tallman, Stéphane de Botton, Hagop M. Kantarjian, Robert Collins, Anthony S. Stein, Mark G. Frattini, Qiang Xu, Alessandra Tosolini, Wendy L. See, Kyle J. MacBeth, Samuel V. Agresta, Eyal C. Attar, Courtney D. DiNardo, Eytan M. Stein